西替利嗪联合卡介菌多糖核酸治疗慢性荨麻疹的效果分析(1)
[摘要] 目的 分析西替利嗪联合卡介多糖核酸治疗慢性荨麻疹的临床疗效。 方法 选择本院2013年1月～2014年12月诊治的82例慢性荨麻疹患者为研究对象，随机将其分为两组，对照组41例给予西替利嗪治疗，实验组41例行西替利嗪联合卡介菌多糖核酸治疗，比较两组临床疗效、不良反应、治疗前后肿瘤坏死因子α(TNF-α)、干扰素γ(IFN-γ)水平。 结果 实验组治疗总有效率为97.6%，与对照组的75.6%比较，差异有统计学意义(P<0.05)。实验组和对照组治疗后TNF-α分别为(24.3±5.5)和(27.0±5.2) ng/L、IFN-γ分别为(47.7±11.2)和(42.6±10.8) μg/L，两组比较，差异有统计学意义(P<0.05)。两组不良反应发生率比较，差异无统计学意义(P>0.05)。 结论 西替利嗪联合卡介菌多糖核酸治疗慢性荨麻疹疗效明确，不良反应少，值得临床推广。
[关键词] 慢性荨麻疹；西替利嗪；卡介菌多糖核酸
[中图分类号] R758.24 [文献标识码] A [文章编号] 1674-4721(2015)06(c)-0082-03
[Abstract] Objective To analyze the clinical effect of chronic urticaria treated by cetirizine combined with BCG-polysaccharide nucleic acid. Methods 82 patients with chronic urticaria treated in our hospital from January 2013 to December 2014 were selected as research objects and randomly divided into two groups.41 cases in control group，cetirizine was provided，while 41 cases in experimental group，cetirizine combined with BCG-polysaccharide nucleic acid was applied.The clinical effect，adverse reaction，and levels of tumor necrosis factor-α(TNF-α) and interferon-γ(INF-γ) before and after treatment was compared respectively. Results The total clinical effective rate in experimental group was 97.6%，while in control group，the rate was 75.6%，with statistical difference(P<0.05).After therapy，there were statistical differences in TNF-α [(24.3±5.5) VS (27.0±5.2)] ng/L and IFN-γ [(47.7±11.2) VS (42.6±10.8)] μg/L in experimental and control groups(P<0.05).The incidence of adverse reactions between two groups didn’t display statistical significance(P>0.05). Conclusion Cetirizine combined with BCG-polysaccharide nucleic acid can obtain a definite on treating chronic urticaria with few adverse reactions，which is worthy of clinical promotion.
[Key words] Chronic urticaria；Cetirizine；BCG-polysaccharide nucleic acid
慢性荨麻疹作为临床一种常见皮肤病，主要表现为局部皮肤瘙痒、红斑或风团，其发病机制较为复杂，昆虫叮咬、食物过敏、感染等多种因素均可引发该病[1]。慢性荨麻疹病程通常较长，至少连续6周，甚至数月或数年，临床治疗难度较大且易复发，给患者日常生活带来困扰[2]。目前治疗慢性荨麻疹常见药物包括西替利嗪、卡介菌多糖核酸注射液等，临床建议行联合治疗。本研究对本院诊治的慢性荨麻疹患者行西替利嗪联合卡介菌多糖核酸治疗，与接受单纯西替利嗪治疗的患者进行对照分析。
1 资料与方法
1.1 一般资料
选择本院2013年1月～2014年12月诊治的82例慢性荨麻疹患者为研究对象，纳入标准：①符合《临床皮肤性病学》[3]中慢性荨麻疹相关诊断标准；②表现出皮肤瘙痒、风团症状，病程>6周；③2周内未服用激素类等相关药物；④年龄>16岁，自愿参与治疗。排除标准：①肝、肾功能不全者；②妊娠期或哺乳期妇女；③免疫调节剂等药物过敏者。随机将患者分为对照组和实验组，各41例，对照组男23例，女18例，年龄18～62岁，平均(31.5±2.2)岁，病程0.5～8.5年，平均(1.5±0.6)年。实验组男24例，女19例，年龄19～64岁，平均(32.0±2.5)岁，病程0.6～8.8年，平均(1.7±0.7)年。两组患者的年龄、病程等一般资料比较，差异无统计学意义(P>0.05)，具有可比性。
1.2 方法
对照组给予单纯西替利嗪(苏州东瑞制药有限公司，国药准字H19980014)治疗，1次/d，10 mg/次；实验组患者行西替利嗪联合卡介菌多糖核酸(浙江万马药业有限公司，国药准字S33020001)治疗，1 ml卡介菌多糖核酸注射液肌内注射，1次/2 d。6周为1个疗程，两组患者均治疗1个疗程。 (潘少英)
[关键词] 慢性荨麻疹；西替利嗪；卡介菌多糖核酸
[中图分类号] R758.24 [文献标识码] A [文章编号] 1674-4721(2015)06(c)-0082-03
[Abstract] Objective To analyze the clinical effect of chronic urticaria treated by cetirizine combined with BCG-polysaccharide nucleic acid. Methods 82 patients with chronic urticaria treated in our hospital from January 2013 to December 2014 were selected as research objects and randomly divided into two groups.41 cases in control group，cetirizine was provided，while 41 cases in experimental group，cetirizine combined with BCG-polysaccharide nucleic acid was applied.The clinical effect，adverse reaction，and levels of tumor necrosis factor-α(TNF-α) and interferon-γ(INF-γ) before and after treatment was compared respectively. Results The total clinical effective rate in experimental group was 97.6%，while in control group，the rate was 75.6%，with statistical difference(P<0.05).After therapy，there were statistical differences in TNF-α [(24.3±5.5) VS (27.0±5.2)] ng/L and IFN-γ [(47.7±11.2) VS (42.6±10.8)] μg/L in experimental and control groups(P<0.05).The incidence of adverse reactions between two groups didn’t display statistical significance(P>0.05). Conclusion Cetirizine combined with BCG-polysaccharide nucleic acid can obtain a definite on treating chronic urticaria with few adverse reactions，which is worthy of clinical promotion.
[Key words] Chronic urticaria；Cetirizine；BCG-polysaccharide nucleic acid
慢性荨麻疹作为临床一种常见皮肤病，主要表现为局部皮肤瘙痒、红斑或风团，其发病机制较为复杂，昆虫叮咬、食物过敏、感染等多种因素均可引发该病[1]。慢性荨麻疹病程通常较长，至少连续6周，甚至数月或数年，临床治疗难度较大且易复发，给患者日常生活带来困扰[2]。目前治疗慢性荨麻疹常见药物包括西替利嗪、卡介菌多糖核酸注射液等，临床建议行联合治疗。本研究对本院诊治的慢性荨麻疹患者行西替利嗪联合卡介菌多糖核酸治疗，与接受单纯西替利嗪治疗的患者进行对照分析。
1 资料与方法
1.1 一般资料
选择本院2013年1月～2014年12月诊治的82例慢性荨麻疹患者为研究对象，纳入标准：①符合《临床皮肤性病学》[3]中慢性荨麻疹相关诊断标准；②表现出皮肤瘙痒、风团症状，病程>6周；③2周内未服用激素类等相关药物；④年龄>16岁，自愿参与治疗。排除标准：①肝、肾功能不全者；②妊娠期或哺乳期妇女；③免疫调节剂等药物过敏者。随机将患者分为对照组和实验组，各41例，对照组男23例，女18例，年龄18～62岁，平均(31.5±2.2)岁，病程0.5～8.5年，平均(1.5±0.6)年。实验组男24例，女19例，年龄19～64岁，平均(32.0±2.5)岁，病程0.6～8.8年，平均(1.7±0.7)年。两组患者的年龄、病程等一般资料比较，差异无统计学意义(P>0.05)，具有可比性。
1.2 方法
对照组给予单纯西替利嗪(苏州东瑞制药有限公司，国药准字H19980014)治疗，1次/d，10 mg/次；实验组患者行西替利嗪联合卡介菌多糖核酸(浙江万马药业有限公司，国药准字S33020001)治疗，1 ml卡介菌多糖核酸注射液肌内注射，1次/2 d。6周为1个疗程，两组患者均治疗1个疗程。 (潘少英)